Shanghai Pharmaceuticals Holding Co Ltd
02607
Company Profile
Business description
Shanghai Pharmaceuticals is the second-largest medical distributor in China by revenue. It is vertically integrated and provides healthcare services in research and development, manufacturing, distribution, and retail. As of 2024, medical distribution is the largest segment, accounting for 91.3% of total revenue. It also has coverage of 31 provinces and cities nationwide.
Contact
No. 200 Taicang Road
Shanghai Pharmaceutical Building
Shanghai200020
CHNT: +86 2163730908
Sector
Healthcare
Stock type
Defensive
Industry
Medical Distribution
Fiscal Year End
31 December 2026
Employees
49,608
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Which of the 3 giant AI IPOs should you buy?
OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.40 | 120.30 | -1.35% |
| CAC 40 | 7,981.27 | 164.33 | 2.10% |
| DAX 40 | 23,298.89 | 618.85 | 2.73% |
| Dow JONES (US) | 46,565.74 | 224.23 | 0.48% |
| FTSE 100 | 10,364.79 | 188.34 | 1.85% |
| HKSE | 25,017.23 | 276.80 | -1.09% |
| NASDAQ | 21,840.95 | 250.32 | 1.16% |
| Nikkei 225 | 52,537.15 | 1,202.53 | -2.24% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,575.32 | 46.80 | 0.72% |
| S&P/ASX 200 | 8,583.60 | 101.40 | -1.17% |
| SSE Composite Index | 3,927.60 | 20.95 | -0.53% |